Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration - Scorecard - MDSpire
Advertisement
Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration
Clinical Scorecard: Longitudinal Analysis of Plasma Proteomics Reveals Inflammatory and Immune Biomarkers Linked to Diagnosis and Treatment Response in Psoriasis After Secukinumab Administration
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Care Setting
Dermatology department in a general hospital, specify type or location.
Key Highlights
Add highlight about the need for validation in larger cohorts.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Adults aged 18 years and older with moderate-to-severe plaque psoriasis.
Secukinumab effectively reduces inflammatory markers associated with psoriasis.
Clinical Best Practices
Integrate patient-reported outcomes in monitoring treatment response.
